Journal of Gastrointestinal Surgery

, Volume 15, Issue 6, pp 942–957

Phosphorylated Insulin-Like Growth Factor 1 Receptor is Implicated in Resistance to the Cytostatic Effect of Gefitinib in Colorectal Cancer Cells

  • Li Yang
  • Jianjun Li
  • Li Ran
  • Feng Pan
  • Xiaoxin Zhao
  • Zhenyu Ding
  • Yuying Chen
  • Qiuping Peng
  • Houjie Liang
Original Article

DOI: 10.1007/s11605-011-1504-z

Cite this article as:
Yang, L., Li, J., Ran, L. et al. J Gastrointest Surg (2011) 15: 942. doi:10.1007/s11605-011-1504-z

Abstract

Introduction

The ability of certain cancer cells to maintain signaling via the phosphoinositide-3-kinase/Akt and/or Ras/mitogen-activated protein kinase (MAPK) pathways has been repeatedly involved in resistance to epidermal growth factor receptor (EGFR) inhibition.

Discussion

We investigated the potential mechanisms of the uncoupling of EGFR from its downstream signals in colorectal cancer (CRC) cells. Alternative growth factor receptors and regulation of downstream pathways in different gefitinib-responsive cell lines were determined. Basal insulin-like growth factor receptor-1β (IGFR-1β) phosphorylation was undetectable or present at very low levels in highly gefitinib-responsive cell lines and was present at strikingly high levels in less responsive cell lines. Further analysis of cell lines representing the most sensitive (Lovo), moderately sensitive (HT29), and most resistant (HCT116) strains was treated with an IGFR-1 inhibitor (AG1024), gefitinib, or both, revealing that elevated IGFR-1β phosphorylation can compensate for the loss of EGFR signaling function. Increased insulin-like growth factor II expression induced by gefitinib or heterodimerization of EGFR and IGFR-1β may trigger IGFR-1β signal transduction via activation of Akt and MAPK. In addition, high levels of EGFR and IGFR-1β phosphorylation were detected in CRC tumor tissue. We also showed that gefitinib- and/or AG1024-induced cytostatic effects could be mediated by glycogen synthase kinase-3β (GSK-3β) activation. Our data suggest that the crosstalk between EGFR and IGFR-1β signaling are likely to contribute to resistance of CRC cells to gefitinib and that measurement of GSK-3β activation may present a potential biomarker for evaluating the antitumor efficacy of receptor tyrosine kinase inhibition.

Keywords

Colorectal cancer Epidermal growth factor receptor Gefitinib Insulin-like growth factor receptor-1β Phosphorylation 

Copyright information

© The Society for Surgery of the Alimentary Tract 2011

Authors and Affiliations

  • Li Yang
    • 1
    • 2
  • Jianjun Li
    • 1
  • Li Ran
    • 2
  • Feng Pan
    • 1
  • Xiaoxin Zhao
    • 1
  • Zhenyu Ding
    • 1
  • Yuying Chen
    • 1
  • Qiuping Peng
    • 3
  • Houjie Liang
    • 1
  1. 1.Department of Oncology, Southwest HospitalThird Military Medical UniversityChongqingPeople’s Republic of China
  2. 2.Department of Oncology, Guizhou Cancer HospitalGuiyang Medical CollegeGuiyangPeople’s Republic of China
  3. 3.Department of Oncology94th HospitalNanchangPeople’s Republic of China

Personalised recommendations